USD
$0.00
(0.00%
)At Close (As of Sep 9, 2025)
$410.59M
Market Cap
22.31
P/E Ratio
0.32
EPS
$8.90
52 Week High
$5.03
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $70M |
Total Revenue | $161M |
Cost Of Revenue | $91M |
Costof Goods And Services Sold | $91M |
Operating Income | $20M |
Selling General And Administrative | $20M |
Research And Development | $15M |
Operating Expenses | $50M |
Investment Income Net | - |
Net Interest Income | $1.5M |
Interest Income | $2.1M |
Interest Expense | $660K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $13M |
Income Before Tax | $13M |
Income Tax Expense | -$1.1M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $14M |
Comprehensive Income Net Of Tax | - |
Ebit | $14M |
Ebitda | $28M |
Net Income | $14M |
Field | Value (USD) |
---|---|
Total Assets | $372M |
Total Current Assets | $184M |
Cash And Cash Equivalents At Carrying Value | $78M |
Cash And Short Term Investments | $78M |
Inventory | $79M |
Current Net Receivables | $23M |
Total Non Current Assets | $188M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $102M |
Intangible Assets Excluding Goodwill | $102M |
Goodwill | $30M |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $3.9M |
Other Non Current Assets | - |
Total Liabilities | $113M |
Total Current Liabilities | $49M |
Current Accounts Payable | $28M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1.6M |
Total Non Current Liabilities | $63M |
Capital Lease Obligations | $11M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $11M |
Other Current Liabilities | $20M |
Other Non Current Liabilities | $53M |
Total Shareholder Equity | $259M |
Treasury Stock | - |
Retained Earnings | -$26M |
Common Stock | $15M |
Common Stock Shares Outstanding | $58M |
Field | Value (USD) |
---|---|
Operating Cashflow | $48M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $14M |
Capital Expenditures | $11M |
Change In Receivables | - |
Change In Inventory | $9.7M |
Profit Loss | - |
Cashflow From Investment | -$11M |
Cashflow From Financing | -$14M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $14M |
Field | Value (USD) |
---|---|
Gross Profit | $70M |
Total Revenue | $161M |
Cost Of Revenue | $91M |
Costof Goods And Services Sold | $91M |
Operating Income | $20M |
Selling General And Administrative | $20M |
Research And Development | $15M |
Operating Expenses | $50M |
Investment Income Net | - |
Net Interest Income | $1.5M |
Interest Income | $2.1M |
Interest Expense | $660K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $13M |
Income Before Tax | $13M |
Income Tax Expense | -$1.1M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $14M |
Comprehensive Income Net Of Tax | - |
Ebit | $14M |
Ebitda | $28M |
Net Income | $14M |
Field | Value |
---|---|
Ex Dividend Date | 2025-03-17 |
Declaration Date | 2025-03-11 |
Record Date | 2025-03-17 |
Payment Date | 2025-04-07 |
Amount | 0.2 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.